Also, these compounds exhibited potent therapeutic effects in murine models of LPS-induced endotoxemia and DMD, suggesting their potential as therapeutic drugs for clinical management of diseases driven by IKK/NF-κB activation. This evidence concerns the gene NFKB1 and serum lipopolysaccharide activity.